These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing, reported early 2004-001117-34 A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma. not-yet-due
Ongoing, reported early 2004-001118-15 Phase II multicenter,open-label, clinical and pharmacokinetic study of Aplidin® as a 3-hour infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the urotheli... not-yet-due
Ongoing, reported early 2004-001253-29 Clinical and pharmacokinetic phase II study of one hour infusion of kahalalide F administered every week to patients with Non Small Cell Lung Cancer Stage IIIB with pleural effusion and stage IV, afte... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-002106-29 A randomized, multicenter, open-label study of Yondelis (ET-743 ecteinascidin) administered by 2 different schedules (weekly for 3 of 4 weeks vs.q3 weeks)in subjects with locally advanced or metastati... 2008-05-05 bad-data
Ongoing, reported early 2004-002692-16 A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-005276-16 An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX alone in subjects with advanced relapsed ovarian cancer 2010-11-12 bad-data
Exempt, with results 2005-001161-34 Phase I-II multicenter, randomized, open-label, clinical and pharmacokinetic study of plitidepsin, administered alone or in combination with dacarbazine, as front-line therapy to subjects with unresec... not-yet-due
Ongoing, reported early 2006-002276-17 Phase II Study of Yondelis® in Men with Advanced Prostate Carcinoma not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-000035-25 A multicenter Phase II clinical trial of neoadjuvant trabectedin (Yondelis) in patients with localized myxoid / round cell liposarcoma. 2010-01-13 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-000794-31 Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-),HER2 overexpressing tumors and BRCA1 or... 2011-08-11 bad-data
Ongoing, reported early 2007-006681-15 Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoral basada en Platino en Pacientes con Cáncer No Microcítico de Pulmón (CNMP) Avanzado con Sobreexpresión de XPG y/o ERCC1, ... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-002326-11 A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS) 2014-08-20 bad-data
Ongoing, reported early 2008-004908-31 Ensayo clínico y farmacocinético de fase II de infusión de 30 minutos de PM02734 (Irvalec®) cada tres semanas en pacientes con cáncer no microcítico de pulmón (CNMP) epidermoide previamente tratado co... not-yet-due
Exempt, with results 2008-004967-21 A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram not-yet-due
Ongoing 2009-010980-18 Efficacité et Tolérance de la Plitidepsine chez les patients souffrant d’un liposarcome dédifférencié (DLPS) avancé, non opérable ou métastatique, en rechute/réfractaire : Une étude exploratoire multi... not-yet-due
Exempt 2009-011041-12 Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité. not-yet-due
Ongoing, reported early 2009-016054-40 Ensayo clínico de fase II, de optimización de dosis, abierto, de Zalypsis® (PM00104) en pacientes con mieloma múltiple recaído/refractario not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-016138-29 Estudio de Fase III, Aleatorizado, Multicéntrico y Abierto de Plitidepsina en combinación con Dexametasona vs. Dexametasona sola en pacientes con Mieloma Múltiple Refractario o en Recaída. 2017-11-20 bad-data
Reported results 2010-019790-15 Open-label, Phase II Clinical Trial of Aplidin (Plitidepsin) in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis 2011-03-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-020325-40 Phase Ib/II, Multicenter, Open-Label, Randomized, Clinical Study with Dose Optimization of Two Different Schedules of Elisidepsin Trifluoroacetate (Irvalec®) as a Single Agent in Patients with Unresec... 2012-05-04 bad-data
Completed, but no date, and reported results 2010-020994-18 Estudio Clínico y Farmacocinético en Fase II de PM00104 (Zalypsis®) en Pacientes con Carcinoma Urotelial Avanzado y/o Metastático que Progresa Después de una Primera Línea de Tratamiento Basado en Pla... bad-data
Listed as ongoing, but also has a completion date and reported results 2010-022221-15 Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis(PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing A... 2012-04-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-022968-13 "Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subex... 2012-08-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-024292-30 A Phase II Study of PM01183 as Second-line Treatment in Patients with Metastatic Pancreatic Cancer 2013-11-28 bad-data
Completed, but no date, and reported results 2011-002172-16 A phase II Controlled Study of PM01183 in Platinum-Resistant / Refractory Advanced Ovarian Cancer Patients. bad-data
Completed, report not yet due 2011-006108-11 A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer. 2018-10-27 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-000548-25 A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination with Gemcitabine and a control arm with Docetaxel as Second-Line Treatment in Unresectable Non-Small... 2016-11-24 bad-data
Ongoing 2014-003773-42 A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors. not-yet-due
Completed, report not yet due 2014-005251-39 Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial) 2018-10-12 not-yet-due
Reported results 2015-000206-18 Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors 2016-08-19 due-trials
Ongoing 2015-001641-89 Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with... not-yet-due
Completed, report not yet due Terminated 2015-001909-14 A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma. 2018-07-02 not-yet-due
Reported results 2015-002395-24 Phase II, Open-Label, Randomized, Controlled Study of PM060184 in Advanced, Hormone Receptor Positive, HER2 negative Breast Cancer Patients in Third or Fourth Line Setting. 2017-10-30 due-trials
Completed, report not yet due 2015-003486-29 Phase II Trial of Plitidepsin (Aplidin®) in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to bortezomib and lenalidomide . 2018-05-29 not-yet-due
Completed, report not yet due 2017-000257-39 A Phase II, Open-label, Multicenter Study of PM060184 in Patients with Advanced Colorectal Cancer after Standard Treatment 2019-02-11 not-yet-due